ALK and lung adenocarcinoma: Histological transformation of lung adenocarcinoma into SCLC is a rare event, which has been described as a key resistance mechanism to tyrosine kinase inhibitor (TKI) treatment in around 5% EGFR-mutant and few ALK-rearranged NSCLC cases (44, 45).